GSK New CEO Cuts, reprioritizes

miamianne67 Invincible Can't you see it? Posts: 5,172 Sept 30, 2015 16:48:33 GMT	GSK New CEO Cuts, reprioritizes Mar 27, 2018 12:18:38 GMT Quote Select Post Deselect Post Link to Post Member Give Gift Back to Top Post by miamianne67 on Mar 27, 2018 12:18:38 GMT Glaxo CEO Dispenses Bitter Pill to Fix R & D In her first year, Emma Walmsley has replaced top managers, pruned the ranks of scientists and shut down clinical trials to narrow the drug-development focus Miami

gatokity
Full Member

Posts: 183

GSK New CEO Cuts, reprioritizes Mar 27, 2018 12:51:06 GMT via mobile icemandios likes this

Quote

Post by gatokity on Mar 27, 2018 12:51:06 GMT

Wondering if these type actions from CEO could help VBIV accelerate Hepislav B and/or LPV to market or increase take over prospects? I think GSK and VBIV are working on the LPV component.

Deleted
Deleted Member

Posts: 0

GSK New CEO Cuts, reprioritizes Mar 27, 2018 14:42:14 GMT

Quote

Post by Deleted on Mar 27, 2018 14:42:14 GMT

Mar 27, 2018 12:18:38 GMT miamianne67 said:

Glaxo CEO Dispenses Bitter Pill to Fix R & D

In her first year, Emma Walmsley has replaced top managers, pruned the ranks of scientists and shut down clinical trials to narrow the drug-development focus

Miami

What a concept... a CEO who clears out the dead wood and prioritizes the compounds that the market needs and the company can reasonably expect to produce... OPK is at least 2 years behind the leadership power curve...

stcks
Eternal

6 rules of successful biotech investing-"RESEARCH, RESEARCH, RESEARCH, PATIENCE, CAPITAL & RESEARCH"

Posts: 3,850

OPKO Investment: Long
Sentiment: Bullish
Recommendation: Hold

GSK New CEO Cuts, reprioritizes Mar 27, 2018 16:06:04 GMT

Quote

Post by stcks on Mar 27, 2018 16:06:04 GMT

Mar 27, 2018 14:42:14 GMT @straightshot said:

Mar 27, 2018 12:18:38 GMT miamianne67 said:

Glaxo CEO Dispenses Bitter Pill to Fix R & D

In her first year, Emma Walmsley has replaced top managers, pruned the ranks of scientists and shut down clinical trials to narrow the drug-development focus

Miami

What a concept... a CEO who clears out the dead wood and prioritizes the compounds that the market needs and the company can reasonably expect to produce... OPK is at least 2 years behind the leadership power curve...

Not sayings that Emma is Steve Jobs. This is what he did with apple when he came back after Sculley.

6 rules of successful biotech investing-"RESEARCH, RESEARCH, RESEARCH, PATIENCE, CAPITAL & RESEARCH"

Deleted
Deleted Member

Posts: 0

GSK New CEO Cuts, reprioritizes Mar 27, 2018 16:38:56 GMT stcks likes this

Quote

Post by Deleted on Mar 27, 2018 16:38:56 GMT

Mar 27, 2018 16:06:04 GMT stcks said:

Mar 27, 2018 14:42:14 GMT @straightshot said:

What a concept... a CEO who clears out the dead wood and prioritizes the compounds that the market needs and the company can reasonably expect to produce... OPK is at least 2 years behind the leadership power curve...

Not sayings that Emma is Steve Jobs. This is what he did with apple when he came back after Sculley.

The point is smart, effective, active management recognizes when changes must be made to insure the viability of the business... especially in a dynamic and fast changing industry... Jobs was a genius... you do not need to be a genius to be a successful CEO... you do, however, need to realize when people and policies are no longer relevant...

Last Edit: Mar 27, 2018 16:40:07 GMT by Deleted

Where Due Diligence meets the Investor Connection

My Notes

Announcements

Recent Threads

Post by miamianne67 on Mar 27, 2018 12:18:38 GMT

Post by gatokity on Mar 27, 2018 12:51:06 GMT

Post by Deleted on Mar 27, 2018 14:42:14 GMT

Post by stcks on Mar 27, 2018 16:06:04 GMT

Post by Deleted on Mar 27, 2018 16:38:56 GMT

Chart